Dehydrocostus Lactone
Based on 3 publication(s) in Google Scholar
Dehydrocostus Lactone ((-)-Dehydrocostus lactone) is a natural sesquiterpene that can be isolated from Saussurea lappa. Dehydrocostus Lactone has multiple activities such as anti-inflammatory, antibacterial, anti-tumor, and immunomodulatory effects. Dehydrocostus Lactone has an MIC of 2 µg/mL against Mycobacterium tuberculosis. Dehydrocostus Lactone can also inhibit the killing activity of cytotoxic T lymphocytes and induce apoptosis in tumor cells.
For research use only. We do not sell to patients.
- Purity : 99.98%
- CAS No.: 477-43-0
- Formula: C15H18O2
- Molecular Weight:230.30
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-N0780
IsoalantolactoneBacterial Inhibitor -
HY-N0141
ParthenolideNF-κB Inhibitor -
HY-N0036
CostunolideApoptosis inducer -
HY-N0038
AlantolactoneApoptosis Inducer -
HY-N0156
Oleanolic acidAutophagy Inducer -
HY-B0284
NifedipineCalcium Channel Antagonist -
HY-N0176
DihydroartemisininAntimalarial Agent -
HY-N0124
DioscinAnticancer Agent -
HY-N2259
CurcumenolCYP3A4 Inhibitor -
HY-N0591R
Dehydrocostus Lactone (Standard)Standard of Dehydrocostus Lactone -
HY-N0551
WedelolactoneCaspase-11 And 5-Lox Inhibitor -
HY-10257
BAY 11-7085NF-κB Activation Inhibitor
Publications Citing Use of MedChemExpress (MCE) Dehydrocostus Lactone
MoreAll Caspase Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
10 μM
Compound: 2
|
Inhibition of IL-1-beta-induced ICAM1 expression in human A549 cells
Inhibition of IL-1-beta-induced ICAM1 expression in human A549 cells
|
[PMID: 9917276] |
| HL-60 | IC50 |
3.7 μM
Compound: Dehydrocostus lactone
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 26832219] |
| HL-60 | IC50 |
5.3 μM
Compound: 1
|
Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry
Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry
|
[PMID: 22985027] |
| HL60/ADR | IC50 |
5.1 μM
Compound: Dehydrocostus lactone
|
Cytotoxicity against human HL60/ADR cells after 72 hrs by MTT assay
Cytotoxicity against human HL60/ADR cells after 72 hrs by MTT assay
|
[PMID: 26832219] |
| K562 | IC50 |
5.3 μM
Compound: Dehydrocostus lactone
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 26832219] |
| K562/A02 | IC50 |
6.6 μM
Compound: Dehydrocostus lactone
|
Cytotoxicity against human K562/A02 cells after 72 hrs by MTT assay
Cytotoxicity against human K562/A02 cells after 72 hrs by MTT assay
|
[PMID: 26832219] |
| KG-1a | IC50 |
10.5 μM
Compound: Dehydrocostus lactone
|
Cytotoxicity against human KG1a cells after 72 hrs by MTT assay
Cytotoxicity against human KG1a cells after 72 hrs by MTT assay
|
[PMID: 26832219] |
| Macrophage | IC50 |
1.2 μg/mL
Compound: 1
|
Antiinflammatory activity in mouse macrophages assessed as LPS-induced nitric oxide production
Antiinflammatory activity in mouse macrophages assessed as LPS-induced nitric oxide production
|
10.1039/C2MD20172K |
| RAW264.7 | IC50 |
>40 μM
Compound: DHCl
|
Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability by MTT assay relative to control
Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability by MTT assay relative to control
|
[PMID: 39149113] |
| RAW264.7 | IC50 |
21.53 μM
Compound: DHCl
|
Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS addition and measured after 24 hrs by Griess assay relative to control
Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS addition and measured after 24 hrs by Griess assay relative to control
|
[PMID: 39149113] |
In Vitro
Dehydrocostus lactone (0-2 mg/L; 48 h) can reduce the viability, induce apoptosis, inhibit the expression of anti-apoptotic proteins, and increase the expression of pro-apoptotic proteins in DU145 cells[1].
Dehydrocostus lactone (0-30 μmol/L; 0.5-8.5 h) can inhibit the phosphorylation of p38 MAPK, MK2, and Akt, the activation of NF-κB, reduce the expression of iNOS and the production of NO, and decrease the mRNA levels of pro-inflammatory cytokines such as TNF-α, IL-6, IL-1β, and IL-12 in RAW264.7 cells treated with LPS (HY-D1056)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:DU145 human prostate cancer cells
-
Concentration:2 mg/L
-
Incubation Time:48 h
-
Result:Decreased the level of anti-apoptotic protein Bcl-xL.
Increased the levels of pro-apoptotic proteins Bax, Bak, Bok, Bik, Bmf, and t-Bid.
Increased the levels of cleaved caspase-8, -9, -7, -3, and cleaved PARP.
-
Cell Line:LPS (HY-D1056)-stimulated RAW264.7 cells.
-
Concentration:0, 3, 5, 10 and 30 µmol/L
-
Incubation Time:Pretreated with 0.5 h, then co-incubation with LPS (HY-D1056) for 0, 0.5, 1, 2, 4 and 8 h
-
Result:Inhibited the protein expression levels of p-p38 MAPK, p-MK2, p-Akt.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (male, 6-8 weeks old) treated LPS[2]
-
Dosage:5, 10 and 20 mg/kg
-
Administration:Intraperitoneal injection (i.p.); single dose
-
Result:Effectively reduced the LPS-stimulated infiltration of inflammatory cells and thickening of the alveolar walls.
Alleviated LPS-induced lung injury scores significantly.
Decreased the cell counts and total protein concentration in BALF.
Reduced the increased MPO activity induced by LPS challenge.
Significantly reduced the mRNA expression levels of iNOS, TNF-α, IL-6, IL-12 and IL-1β in lung tissues.
Chemical Information
-
CAS No. 477-43-0
-
Appearance Solid
-
Molecular Weight 230.30
-
Formula C15H18O2
-
Color White to off-white
-
SMILES
O=C(O[C@@]([C@@]1([H])C(CC[C@@]21[H])=C)([H])[C@@]3([H])CCC2=C)C3=C
-
Synonyms
(-)-Dehydrocostus lactone; Epiligulyl oxide
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Phytother Res
Dehydrocostus Lactone Suppresses Hepatocellular Carcinoma by Inhibiting Protein Tyrosine Kinase-7 Mediated β-Catenin Signaling. [Abstract]2026 Jun 5. PMID: 42248674 -
ACS Omega
Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]2024 Feb 28;9(10):11870-11882. PMID: 38496939 -
Bioorg Chem
Dehydrocostus lactone promotes ferroptosis by regulating the HMOX1/CDK1 axis during liver cancer treatment. [Abstract]2026 Jan:168:109349. PMID: 41389607
Solvent & Solubility
In Vitro:
DMSO : 250 mg/mL (1085.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 15 mg/mL (65.13 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (9.03 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (9.03 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[2]. Nie Y, Wang Z, Chai G, et al. Dehydrocostus Lactone Suppresses LPS-induced Acute Lung Injury and Macrophage Activation through NF-κB Signaling Pathway Mediated by p38 MAPK and Akt. Molecules. 2019;24(8):1510. [Content Brief]
[3]. Taniguchi M, et al. Costunolide and dehydrocostus lactone as inhibitors of killing function of cytotoxic T lymphocytes. Biosci Biotechnol Biochem. 1995 Nov;59(11):2064-7. [Content Brief]
[4]. Cantrell CL, et al. Antimycobacterial activities of dehydrocostus lactone and its oxidation products. J Nat Prod. 1998 Oct;61(10):1181-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 4.3422 mL | 21.7108 mL | 43.4216 mL | 108.5541 mL |
| 5 mM | 0.8684 mL | 4.3422 mL | 8.6843 mL | 21.7108 mL | |
| 10 mM | 0.4342 mL | 2.1711 mL | 4.3422 mL | 10.8554 mL | |
| 15 mM | 0.2895 mL | 1.4474 mL | 2.8948 mL | 7.2369 mL | |
| 20 mM | 0.2171 mL | 1.0855 mL | 2.1711 mL | 5.4277 mL | |
| 25 mM | 0.1737 mL | 0.8684 mL | 1.7369 mL | 4.3422 mL | |
| 30 mM | 0.1447 mL | 0.7237 mL | 1.4474 mL | 3.6185 mL | |
| 40 mM | 0.1086 mL | 0.5428 mL | 1.0855 mL | 2.7139 mL | |
| 50 mM | 0.0868 mL | 0.4342 mL | 0.8684 mL | 2.1711 mL | |
| 60 mM | 0.0724 mL | 0.3618 mL | 0.7237 mL | 1.8092 mL | |
| DMSO | 80 mM | 0.0543 mL | 0.2714 mL | 0.5428 mL | 1.3569 mL |
| 100 mM | 0.0434 mL | 0.2171 mL | 0.4342 mL | 1.0855 mL |
Dehydrocostus Lactone Related Classifications
HY-N0591 Related Classifications
Powered by Bioz